FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * GADICKE ANSBERT   2. Issuer Name and Ticker or Trading Symbol Pharmasset Inc [VRUS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O MPM ASSET MANAGEMENT, 200 CLARENDON ST., 54TH FLOOR 3. Date of Earliest Transaction (Month/Day/Year) 06/13/2008 (Street) BOSTON, MA 02116 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/13/2008   S   1,091 D $ 19 15,676 D   Common Stock 06/13/2008   S   230 D $ 19 3,303 I See Footnote (1) Common Stock 06/16/2008   S   15,387 D $ 19 289 D   Common Stock 06/16/2008   S   3,242 D $ 19 61 I See Footnote (1) Common Stock 06/16/2008   S   83 D $ 19.08 206 D   Common Stock 06/16/2008   S   17 D $ 19.08 44 I See Footnote (1) Common Stock 06/16/2008   S   41 D $ 19.11 165 D   Common Stock 06/16/2008   S   9 D $ 19.11 35 I See Footnote (1) Common Stock 06/16/2008   S   83 D $ 19.37 82 D   Common Stock 06/16/2008   S   17 D $ 19.37 18 I See Footnote (1) Common Stock 06/16/2008   S   82 D $ 19.38 0 D   Common Stock 06/16/2008   S   18 D $ 19.38 0 I See Footnote (1) Common Stock               2,655,463 I See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
GADICKE ANSBERT C/O MPM ASSET MANAGEMENT 200 CLARENDON ST., 54TH FLOOR BOSTON, MA 02116		X

Signatures

/s/ Ansbert Gadicke		06/17/2008
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The shares were sold by The Gadicke Irrevocable Trust, of which Mr. Gadicke is a trustee.
(2)	These shares are held as follows: 1,182,339 shares by BB BioVentures, L.P. ("BBBV"), 159,391 shares by MPM BioVentures Parallel Fund, L.P. ("BV PF"), 14,099 shares by MPM Asset Management Investors 1999 LLC ("AM 1999"), 68,671 shares by MPM BioVentures III, L.P., ("BV III"), 1,021,244 shares by MPM BioVentures III-QP, L.P. ("BV III QP"), 86,303 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"), 30,844 shares by MPM BioVentures III Parallel Fund, L.P. ("BV III PF"), 24,277 shares held by MPM Asset Management Investors 2004 BVIII LLC ("AM BV III") and 68,295 by MPM BioVentures III GP, L.P. ("BV III GP"). MPM BioVentures I, L.P. ("BV I") and MPM BioVentures I LLC ("BV I LLC") are the direct and indirect general partners of BV PF. BAB BioVentures L.P. ("BAB BV"), BAB BioVentures, N.V. ("BAB NV") and BV I LLC are the direct and indirect general partners of BBBV. The Reporting Person is a manager of AM 1999 and BV I LLC. BV III GP and MPM BioVentures III LLC ("BV III LLC") are the direct and indirect general partners of BV III, BV III QP, BV III PF and BV KG. The Reporting Person is a Series A member of BV III LLC and a manager of AM BV III. The Reporting Person disclaims beneficial ownership of all such shares except to the extent of his proportionate pecuniary interests therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.